Search results for "PSORIASIS"

showing 10 items of 193 documents

Psoriasis predisposition and occupational triggering factors in the appraisal of occupational medical expertises

2014

Summary Background Psoriasis is an immune-mediated disease with a genetic background. Local psoriatic changes can be triggered by exogenous mechanical or irritant factors. Causative occupational factors have to be distinguished from the spontaneous course of psoriasis in occupational medical evaluations. The objective of this work is to demonstrate the medico-legal grounds for a homogenous assessment. Patients and methods The presented recommendations were developed in a working group for Occupational and Environmental Dermatology (ABD) and the German contact dermatitis group (DKG) of the German Dermatologic Society (DDG) based on the German medico-legal framework. Results Causality between…

medicine.medical_specialtyRehabilitationbusiness.industrymedicine.medical_treatmentDermatologyGuidelineDiseasemedicine.diseaseCausalitylanguage.human_language3. Good healthSurgeryGermanExpert witnessPsoriasisFamily medicinemedicinelanguagePosition paperbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Rational for statin use in psoriatic patients

2013

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory pro…

medicine.medical_specialtyStatinmedicine.drug_classAtorvastatinDermatologyDiseasePharmacologychemistry.chemical_compoundPsoriasisInternal medicinemedicineAnimalsHumansPsoriasiscardiovascular diseasesSkinCholesterolbusiness.industrynutritional and metabolic diseasesPsoriasis Statins Cholesterol Atorvastatin Fluvastatin SimvastatinGeneral Medicinemedicine.diseaseTreatment OutcomechemistrySimvastatinlipids (amino acids peptides and proteins)Dermatologic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatin
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct

S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.

2019

The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…

medicine.medical_specialtyTuberculosisAdolescentMEDLINEDermatologyDiseaseDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisBiological Factors0302 clinical medicinePharmacotherapyQuality of life (healthcare)PsoriasismedicineHumansPsoriasisChildBiosimilar PharmaceuticalsTonsillectomybusiness.industryVaccinationmedicine.diseaseSkin CareAnti-Bacterial AgentsFamily medicineUltraviolet TherapyDermatologic AgentsbusinessGuttate psoriasisImmunosuppressive AgentsJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regime…

2013

Abstract Background:  Interleukin-17A has major proinflammatory activity in psoriatic lesional skin. Objectives:  Assess the efficacy and safety of secukinumab, a fully human IgG1κ monoclonal anti-interleukin-17A antibody, in moderate-to-severe plaque psoriasis in a phase II regimen-finding study. Methods:  404 patients were randomised to subcutaneous placebo (67 patients) or one of three secukinumab 150 mg induction regimens: Single (week 0; 66 patients), Early (weeks 0, 1, 2, 4; 133 patients), and Monthly (weeks 0, 4, 8; 138 patients). The primary outcome was ≥75% improvement from baseline Psoriasis Area and Severity Index (PASI) score at week 12. PASI 75 responders from active treatment …

medicine.medical_specialtybusiness.industryDermatologyPlaceboSurgeryDiscontinuationlaw.inventionRegimenRandomized controlled trialMaintenance therapyPsoriasis Area and Severity IndexlawInternal medicinemedicineSecukinumabbusinessAdverse effectBritish Journal of Dermatology
researchProduct

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab

2018

Hidradenitis suppurativa (HS) is a disorder of the apocrine gland causing a chronic, recurrent and painful inflammation. It is a disabilitating condition and, though many therapeutic options are available, the response is often ineffective in most cases and patients can present many recurrences with physical and psychological sequelae. Recent data had shown increased interleukin (IL)-17 serum levels in patients with HS. Psoriasis is a chronic immune-mediated inflammatory disorder and new evidences have shown the role of Th17 cells in its pathogenesis and the therapeutic efficacy of anti-IL-17 antibodies. We present a case of a patient suffering from psoriasis and HS successfully treated wit…

medicine.medical_specialtybusiness.industryInterleukin-17ApocrineInterleukinCase ReportInflammationDermatologymedicine.diseaseDermatologyPathogenesisHidradenitis suppurativa030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPsoriasismedicinePsoriasisHidradenitis suppurativaSecukinumabInterleukin 17medicine.symptombusinessAnnals of Dermatology
researchProduct

Intensification therapy with golimumab: a new treatment strategy for moderate-severe refractory psoriasis

2014

medicine.medical_specialtybusiness.industryMEDLINEArthritisDermatologymedicine.diseaseGolimumabPharmacotherapyRefractoryPsoriasisInternal medicineSeverity of illnessmedicinePhysical therapybusinessmedicine.drugIntensification therapyInternational Journal of Dermatology
researchProduct

2020

Background Psoriasis is a frequent chronic inflammatory cytokine‐mediated skin disease and was identified to be an independent risk factor for the occurrence of myocardial infarction (MI). However, data about the impact of psoriasis on mortality and other in‐hospital adverse events in the setting of MI are sparse and inconsistent. Methods and Results The nationwide German inpatient sample of the years 2005 to 2016 was used for statistical analysis. Hospitalized patients with MI were stratified for the presence of psoriasis and the impact of psoriasis on in‐hospital events was investigated. Overall, 3 307 703 patients with MI (37.6% females, 56.8% aged ≥70 years) were treated in Germany (20…

medicine.medical_specialtybusiness.industryMortality rateDisease030204 cardiovascular system & hematologymedicine.disease030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasismedicineMyocardial infarctionRisk factorCardiology and Cardiovascular MedicinebusinessJournal of the American Heart Association
researchProduct

398 Safety of 62-week treatment of psoriasis with cyclosporine

2017

medicine.medical_specialtybusiness.industryPsoriasisMedicineCell BiologyDermatologybusinessmedicine.diseaseMolecular BiologyBiochemistryDermatologyJournal of Investigative Dermatology
researchProduct

Treg activation status depends on psoriasis therapy regime

2020

medicine.medical_specialtybusiness.industryPsoriasismedicineMEDLINEHumansPsoriasisTh17 CellsDermatologymedicine.diseasebusinessT-Lymphocytes RegulatoryDermatologyJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct